Search Results - "CROWN, J. P. A"

Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial by Buisseret, L., Pommey, S., Allard, B., Garaud, S., Bergeron, M., Cousineau, I., Ameye, L., Bareche, Y., Paesmans, M., Crown, J.P.A., Di Leo, A., Loi, S., Piccart-Gebhart, M., Willard-Gallo, K., Sotiriou, C., Stagg, J.

“…CD73 is an ecto-enzyme that promotes tumor immune escape through the production of immunosuppressive extracellular adenosine in the tumor microenvironment…”
Get full text

Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-98 trial by Pestalozzi, B.C., Francis, P., Quinaux, E., Dolci, S., Azambuja, E., Gelber, R.D., Viale, G., Balil, A., Andersson, M., Nordenskjöld, B., Gnant, M., Gutierrez, J., Láng, I., Crown, J.P.A., Piccart-Gebhart, M.

“…Breast cancer central nervous system (CNS) metastases are an increasingly important problem because of high CNS relapse rates in patients treated with…”
Get full text

Predictors of 5-year survival and curability in small cell lung cancer by Crown, J P, Chahinian, A P, Jaffrey, I S, Glidewell, O J, Kaneko, M, Holland, J F

“…A retrospective analysis of various characteristics in 81 small cell lung cancer patients treated at the Mount Sinai Medical Center, New York, from 1974 to…”
Get more information

Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response by Seidman, A D, Reichman, B S, Crown, J P, Yao, T J, Currie, V, Hakes, T B, Hudis, C A, Gilewski, T A, Baselga, J, Forsythe, P

“…Two phase II clinical trials were performed to determine efficacy and tolerability of paclitaxel (Taxol; Bristol-Myers Squibb Co, Wallingford, CT) and…”
Get more information

Sequential Dose-Dense Doxorubicin, Paclitaxel, and Cyclophosphamide for Resectable High-Risk Breast Cancer: Feasibility and Efficacy by HUDIS, C, SEIDMAN, A, SURBONE, A, UHLENHOPP, M, RIEDEL, E, YAO, T. J, NORTON, L, BASELGA, J, RAPTIS, G, LEBWOHL, D, GILEWSKI, T, MOYNAHAN, M, SKLARIN, N, FENNELLY, D, CROWN, J. P. A

“…Dose-dense chemotherapy is predicted to be a superior treatment plan. Therefore, we studied dose-dense doxorubicin, paclitaxel, and cyclophosphamide…”
Get full text

Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer by Hudis, C A, Seidman, A D, Crown, J P, Balmaceda, C, Freilich, R, Gilewski, T A, Hakes, T B, Currie, V, Lebwohl, D E, Baselga, J, Raptis, G, Gollub, M, Robles, M, Bruno, R, Norton, L

“…Because docetaxel (Taxotere, RP 56976; Rhone-Poulenc Rorer, Antony, France) appeared to be active against breast cancer in phase I trials, we performed this…”
Get more information

Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer by Reichman, B S, Seidman, A D, Crown, J P, Heelan, R, Hakes, T B, Lebwohl, D E, Gilewski, T A, Surbone, A, Currie, V, Hudis, C A

“…A phase II study of Taxol (paclitaxel; Bristol-Myers Squibb Co, Princeton, NJ) as initial chemotherapy for metastatic breast cancer was conducted. Recombinant…”
Get more information

Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer by Seidman, A D, Norton, L, Reichman, B S, Crown, J P, Yao, T J, Heelan, R, Hakes, T B, Lebwohl, D E, Gilewski, T A, Surbone, A

“…Single-agent paclitaxel (TAXOL) was administered to 79 patients with stage IV breast cancer. Twenty-eight patients had no prior chemotherapy (for metastatic…”
Get more information